BBIO

BridgeBio Pharma, Inc. 2025 Form 10-K Summary

Business Context and Reporting Period

This Annual Report on Form 10-K covers the fiscal year ended December 31, 2025. BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company focused on genetic diseases. The company operates a portfolio model with one major commercial product, Attruby (acoramidis) in the U.S. and Beyonttra (acoramidis) internationally, and a pipeline of late-stage candidates for achondroplasia, limb-girdle muscular dystrophy, and autosomal dominant hypocalcemia.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The company reported a net loss attributable to common stockholders of $724.9 million for 2025. Working capital was $509.8 million as of December 31, 2025.

Material Changes vs. Prior Period

• Revenue Surge: Total revenue increased 126% year-over-year, driven primarily by a $359.5 million increase in net product revenue from the U.S. commercial launch of Attruby (approved Nov 2024) and international approvals for Beyonttra (EU, UK, Japan).
• License Revenue Decline: License and services revenue decreased by $90.5 million, primarily due to the recognition of $207.7 million in upfront fees in 2024 (Bayer and Kyowa Kirin agreements) compared to milestone-driven revenue in 2025.
• Expense Growth: Selling, general, and administrative (SG&A) expenses increased by $242.3 million to $531.2 million, reflecting the build-out of the commercial organization for Attruby. Research and development (R&D) expenses decreased by $54.5 million to $452.0 million due to reprioritization of programs.
• Debt Structure: The company issued $575.0 million in 2031 Convertible Senior Notes in February 2025 and repaid its $450.0 million term loan. It also entered into a $300.0 million royalty monetization agreement in June 2025.

Guidance, Outlook, and Management Commentary

• Commercial Momentum: Attruby achieved >25% share of new-to-brand prescriptions in the U.S. with 7,804 unique patient prescriptions as of Feb 2026. Beyonttra achieved >50% NBRx share in Germany within its first year.
• Pipeline Milestones:
  • Infigratinib (Achondroplasia): Positive Phase 3 PROPEL 3 topline data reported Feb 2026; NDA/MAA submission expected H2 2026.
  • Encaleret (ADH1): Positive Phase 3 CALIBRATE topline data reported Oct 2025; NDA submission expected H1 2026.
  • BBP-418 (LGMD2I/R9): Positive Phase 3 FORTIFY interim data reported Oct 2025; NDA submission expected H1 2026.
• Liquidity: Management expects cash and marketable securities ($587.5 million) plus product revenue to fund operations for at least the next 12 months. However, the company anticipates continued net losses and may require additional funding for future development and commercialization.
• Risks: Key risks include the commercial success of Attruby/Beyonttra, reimbursement pressures (including potential Most-Favored-Nation pricing models), reliance on third-party manufacturers, and the uncertainty of clinical trial outcomes for pipeline candidates.

Investor Verification Checklist

• Attruby Commercialization: Verify the sustainability of the >25% U.S. market share and the impact of Medicare Part D out-of-pocket caps ($2,000) on patient access.
• Debt and Royalty Obligations: Review the terms of the $1.87 billion in convertible notes and the $866.3 million in deferred royalty obligations, specifically the caps and triggers for the Funding Agreement and Royalty Purchase Agreement.
• Regulatory Submissions: Monitor the timing and acceptance of NDAs for infigratinib, encaleret, and BBP-418 in H1/H2 2026.
• International Partnerships: Assess the performance of Bayer (EU) and Alexion (Japan) in commercializing Beyonttra and the resulting royalty streams.
• Capital Requirements: Evaluate the runway provided by current cash balances against the projected costs of launching three additional medicines globally in 2026.